Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma. (Q64990659)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29855141%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

title

Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma (English)

1 reference

29 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29855141%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

author name string

Chengdu Sun

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29855141%20AND%20SRC:MED&resulttype=core&format=json

2

1 reference

29 March 2020

Yi Feng

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29855141%20AND%20SRC:MED&resulttype=core&format=json

3

1 reference

29 March 2020

Qingzhu Jia

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29855141%20AND%20SRC:MED&resulttype=core&format=json

4

1 reference

29 March 2020

Bo Zhu

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29855141%20AND%20SRC:MED&resulttype=core&format=json

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29855141%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

publication date

31 May 2018

1 reference

Journal of Cellular and Molecular Medicine

29 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29855141%20AND%20SRC:MED&resulttype=core&format=json

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

29 March 2020

cites work

1 reference

12 December 2020

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

1 reference

12 December 2020

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

1 reference

12 December 2020

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

1 reference

12 December 2020

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.

1 reference

12 December 2020

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations

1 reference

12 December 2020

1 reference

12 December 2020

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 December 2020

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

12 December 2020

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

12 December 2020

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

1 reference

12 December 2020

Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing

1 reference

12 December 2020

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

1 reference

12 December 2020

Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory

1 reference

12 December 2020

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

1 reference

12 December 2020

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

1 reference

12 December 2020

1 reference

12 December 2020

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

1 reference

12 December 2020

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

12 December 2020

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

12 December 2020

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors

1 reference

12 December 2020

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas

1 reference

12 December 2020

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors

1 reference

12 December 2020

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

1 reference

12 December 2020

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

1 reference

12 December 2020

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).

1 reference

12 December 2020

Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

1 reference

12 December 2020

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

1 reference

12 December 2020

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.

1 reference

12 December 2020

Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives

1 reference

12 December 2020

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

1 reference

12 December 2020

Doubling Down on BRCA-Mutated Cancer.

1 reference

12 December 2020